KRAS and neoplasm: Since mutations in the KRAS gene are the earliest genetic variation in PDAC [176] and lead to a loss of NK cells in precancerous stages, several strategies to enhance NK cell tumor infiltration [208] and NK adoptive cell transfer are being explored as promising therapeutic interventions.